UCB’s Kola joins Astex board
pharmafile | June 5, 2010 | Appointment | Research and Development | Astex, UCB, appointment, research and development
Dr Ismail Kola has joined the board of directors at UK biotech company Astex Therapeutics.
Astex’s non-executive chairman Peter Fellner said: “I am delighted that Ismail has decided to join Astex’s Board at this time in the company’s development. With three of our products about to enter into phase II clinical trials, Ismail’s exceptionally broad experience in pharmaceutical research and development will be an enormous asset to Astex as we continue to capture the value of the company’s technology and products going forward.”
Dr Kola is currently president of new medicines at UCB, having joined the Belgium pharma company from Schering-Plough in November 1999.
At Schering-Plough he served as senior VP of discovery research and early clinical research and experimental medicine and prior to this held senior positions at Merck and Pharmacia (now part of Pfizer).
Related Content

UCB presents positive results for fenfluramine in CDKL5 deficiency disorder
UCB has announced positive results from its phase 3 GEMZ study, showing that fenfluramine can …

UCB announces first-in-patient trial success for galvokimig in atopic dermatitis
UCB has reported positive early clinical trial results for galvokimig, an investigational therapy for adults …

PlasmidFactory founder Dr. Martin Schleef honoured with the NRW Innovation Award 2025
The founder and long-standing CEO of PlasmidFactory, Dr. Martin Schleef, was honoured in Düsseldorf with …






